Author:
Bartl Stefan,Xie Yuanyun,Potluri Nalini,Kesineni Ratnesh,Hencak Katlin,Cengio Louisa Dal,Balazs Katja,Oueslati Abid,Parth Michela,Salhat Nina,Siddu Alberto,Smrzka Oskar,Cicchetti Francesca,Straffler Günther,Hayden Michael R.,Southwell Amber L.
Reference72 articles.
1. Modelling the human blood-brain barrier to understand protein spread in Huntington’s disease;Alpaugh,2021
2. An intrabody drug (rAAV6-INT41) reduces the binding of N-terminal huntingtin fragment(s) to DNA to basal levels in PC12 cells and delays cognitive loss in the R6/2 animal model;Amaro;J. Neurodegener. Dis.,2016
3. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death;Arrasate;Nature,2004
4. Weight loss in Huntington disease increases with higher CAG repeat number;Aziz;Neurology,2008
5. Transcellular spreading of huntingtin aggregates in the Drosophila brain;Babcock;Proc. Natl. Acad. Sci. U. S. A.,2015